Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Edible Garden Preliminary Sales Results During Key Thanksgiving Time Period Increased 26.9% in 2025
-
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
-
BitMEX Integrates Mercuryo On-ramp to Introduce Fiat-to-Crypto Conversion
-
Bitget Launchpool adds Stable (STABLE) with over 47.8M in Token Rewards
-
DoorDash Chief Analytics Officer Breaks Down Insights from the “State of Local Commerce” Report on YourUpdateTV
-
Asmodee - Pre Stabilization Notice
-
Exodus Movement, Inc. November 2025 Treasury Update and Monthly Metrics
-
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
-
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
-
Hacken Releases MEXC’s Audit, Confirms Full Asset Backing and Strengthened Transparency Standards
-
Heineken® 0.0 x LÕK serve up the world’s first padel racket with a built-in bottle opener
-
Digital Culture Group Dominates Awards Season With Wins in AI Innovation
-
Aya Gold & Silver Reports High-Grade Silver Results at Zgounder
-
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
-
Gencor Releases Fourth Quarter and Fiscal Year 2025 Results
-
Harfang and SOQUEM Expand Gold Footprint at Menarik West, Québec
-
CRML Executes Term-Sheet for 50/50 Joint Venture With EU and NATO Member, Romania, Creating a Fully Integrated Mine-to-Processing Supply Chain for Long-Term Security for the European Manufacturing &am
-
Parex Resources Announces Update on Discussions with GeoPark Regarding a Potential Business Combination
-
Premier American Uranium Files Technical Report for Cebolleta Uranium Project
-
Asante Gold Provides Update on Bibiani Sulphide Treatment Plant Ramp-Up
-
TopBuild Hosting 2025 Investor Day on December 9, Providing Strategic Outlook on Business
-
ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science
-
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
-
Safe Harbor Launches New Payroll Cashflow Solution and Announces Major Banking Win with Canopy HR
-
Americold Realty Trust, Inc. Announces Participation at Investor Conference
-
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
-
Eloro Resources Intersects Highest Silver Interval to Date at its Iska Iska project, Southern Bolivia with 72 metres grading 294.81 g/t Silver within a broader interval of 180 metres grading 164.74 g/
-
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
-
Plug to Participate in Wells Fargo Energy & Power Conference
-
Lantronix to Launch New Edge AI Solutions at CES 2026
-
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
-
Ethereum-Based Mutuum Finance (MUTM) Advances Through Roadmap Phase 2 With Over $19.2 Raised
-
ILLR Secures Nasdaq Listing Extension with Clear Path to Full Compliance
-
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
-
OMNI-LITE INDUSTRIES ANNOUNCES NEW FIVE-YEAR AGREEMENT WITH MAJOR GLOBAL JET ENGINE MANUFACTURER
-
TransAlta Signs Long-Term Agreement for 700 MW at Centralia Facility Enabling Coal to Natural Gas Conversion
-
G-III Apparel Group, Ltd. Reports Third Quarter Fiscal 2026 Results and Updates Fiscal 2026 Outlook; Initiates First Ever Quarterly Dividend Program
-
CRML Executes Term-Sheet for 50/50 Joint Venture With EU and NATO Member, Romania, Creating a Fully Integrated Mine-to-Processing Supply Chain for Long-Term Security for the European Manufacturing & N
-
Safe Harbor Launches New Payroll Cashflow Solution and Announces Major Banking Win with Canopy HR
-
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
-
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions
-
Ollie’s Bargain Outlet Holdings, Inc. Announces Third Quarter Fiscal 2025 Results
-
Skyharbour and JV Partner Orano Announce Extensive Exploration and Drilling Plans for 2026 at Preston Uranium Project
-
Lungpacer Achieves Commercial Milestone as Leading U.S. Hospital Performs First AeroPace® Procedures to Help Patients Liberate from Mechanical Ventilation
-
Transpire Bio Manufacturing Facility Receives the Establishment Inspection Report Following a Pre-Approval Inspection by the U.S. FDA
-
SailPoint Announces Fiscal Third Quarter 2026 Results
-
Woof Gang, America’s Largest Premium Pet Grooming Brand, Expands into New States
-
Plug to Participate in Wells Fargo Energy & Power Conference
-
Aeluma Files New Patent That Enhances Intellectual Property for Large-Scale High Performance Semiconductor Manufacturing
-
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
